Amblyopia is a significant public health problem that affects between 2% and 5% of adults.
1 It is the leading cause of monocular vision loss in the United States among people younger than 40 years.
2 Although vision screening for amblyopia is widely endorsed,
3 4 5 it has been the subject of skepticism,
6 7 8 and the benefit of treating certain amblyogenic conditions has also been questioned.
9 10 The actual effect of screening for amblyopia and treating it on the prevalence of this disease is hard to quantify, since for ethical reasons, no comparison studies to nontreatment have been performed. Studies of the prevalence of amblyopia in developed countries where medical treatment is available, such as the United Kingdom, Sweden, and Australia, quote rates between 0.5% and 3%.
11 12 13 In developing countries, where national screening methods are less available and medical treatment is not always at hand, a much higher rate of amblyopia was expected. However, the reported rate of amblyopia is not much different: 0.3% in southern Jordan,
14 1.29% in rural Indonesia,
15 and 2.5% in northern Mexico.
16 Moreover, population-based studies have shown that the prevalence of amblyopia can be different between ethnic groups, even when they live in the same environment.
17 It is therefore impossible to draw conclusions regarding the efficacy of screening and treatment by comparing the rate of amblyopia quoted in these studies in which different methods were used in different environments and in different ethnic groups.